All of the enacted and pending state biosimilars laws restrict substitution to biosimilars that FDA has approved as interchangeable with a reference biologic. Similar to generics substitution practices, the laws all allow a physician to prohibit substitution, and none require physician approval prior to substitution.

Unlike generics substitution practices, most of the biosimilar substitution laws require that pharmacists notify physicians after a substitution is made and/or maintain